联环药业上涨7.42%，报29.84元/股

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has shown a significant stock price increase and strong revenue growth, indicating a positive market response and operational performance despite a decline in net profit [1] Company Overview - Jiangsu Lianhuan Pharmaceutical is located in Yangzhou, Jiangsu Province, and is recognized as a national high-tech enterprise [1] - The company integrates research and development, production, and sales, specializing in various pharmaceutical forms including tablets, hard capsules, suppositories, and granules, with an annual production capacity of 5 billion units [1] - Its main product lines include urological, antihistamine, cardiovascular, steroid hormone, and antibiotic categories, with over 100 varieties, including key products like the first-class new drug Aipulete and second-class new drug Ebastine [1] - The company boasts a high-end R&D team of nearly 200 members and multiple research platforms [1] Financial Performance - For the period from January to March 2025, the company achieved a revenue of 628 million yuan, representing a year-on-year growth of 18.78% [1] - The net profit attributable to shareholders was 23.06 million yuan, reflecting a year-on-year decrease of 29.15% [1] - As of March 31, the number of shareholders was 30,300, with an average of 9,416 circulating shares per person [1] Market Activity - On August 19, the company's stock price increased by 7.42%, reaching 29.84 yuan per share, with a trading volume of 699 million yuan and a turnover rate of 8.57% [1] - The total market capitalization of Jiangsu Lianhuan Pharmaceutical is 8.518 billion yuan [1]